Ceftobiprole regulatory update

JNJ's Janssen-Cilag unit submitted an MAA to EMEA for ceftobiprole to treat complicated skin and soft tissue/skin structure infections (cSSTIs/cSSSIs). The submission triggers a CHF12 million ($9.7 mi...